Who owns XENE?
Institutional ownership of Xenon Pharmaceuticals Inc. from Form 13F, Q2 2026
315 institutional managers reported holding Xenon Pharmaceuticals Inc. (XENE) in Form 13F filings for Q2 2026, with 101,110,526 shares worth $6.1B. The largest reported holder was FMR LLC. Managers that filed both quarters added a net 733,459 shares (+0.8%). 46 opened new positions and 22 sold out.
- Funds holding
- 315
- Value held
- $6.1B
- New / sold out
- 46 / 22
- Net shares, same filers
- +0.8%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of XENE
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| FMR LLC | $582M | 9.5% | 9,647,998 | Trimmed |
| BlackRock, Inc. | $454M | 7.4% | 7,522,482 | Added |
| Avoro Capital Advisors LLC | $349M | 5.7% | 5,777,777 | Unchanged |
| Polar Capital Holdings Plc | $276M | 4.5% | 4,570,556 | Added |
| Driehaus Capital Management LLC | $267M | 4.4% | 4,418,557 | Trimmed |
| Jupiter Topco LLC | $253M | 4.1% | 4,186,519 | First report |
| Price T Rowe Associates Inc | $196M | 3.2% | 3,248,219 | Added |
| JPMorgan Chase & Co | $157M | 2.6% | 2,617,360 | Added |
| Capital International Investors | $143M | 2.3% | 2,361,639 | Trimmed |
| T. Rowe Price Investment Management, Inc. | $131M | 2.1% | 2,168,581 | Added |
| State Street Corp | $119M | 1.9% | 1,969,629 | Added |
| Two Sigma Investments, LP | $99.2M | 1.6% | 1,642,848 | Added |
| Deerfield Management Company, L.p. | $97.5M | 1.6% | 1,615,696 | Unchanged |
| Affinity Asset Advisors, LLC | $96.3M | 1.6% | 1,595,000 | Trimmed |
| Westfield Capital Management Co LP | $91.0M | 1.5% | 1,507,294 | Added |
| Alliancebernstein L.p. | $90.8M | 1.5% | 1,562,276 | Added |
| Franklin Resources Inc | $86.8M | 1.4% | 1,437,712 | Added |
| Wellington Management Group LLP | $86.0M | 1.4% | 1,425,492 | Trimmed |
| Citadel Advisors LLC | $84.6M | 1.4% | 1,401,242 | Trimmed |
| Geode Capital Management, LLC | $82.7M | 1.4% | 1,370,114 | Added |
| Siren, L.L.C. | $79.6M | 1.3% | 1,318,564 | Unchanged |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $77.9M | 1.3% | 1,290,731 | Trimmed |
| Pictet Asset Management Holding SA | $71.6M | 1.2% | 1,187,723 | Added |
| Braidwell LP | $68.3M | 1.1% | 1,131,452 | Trimmed |
| Nuveen, LLC | $59.9M | 1.0% | 993,126 | Added |
Share of 13F holdings is each fund's shares as a share of the 101,110,526 XENE shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Price T Rowe Associates Inc Added+$116M
- BlackRock, Inc. Added+$114M
- T. Rowe Price Investment Management, Inc. Added+$73.4M
- Two Sigma Investments, LP Added+$62.6M
- Invesco Ltd. Added+$51.0M
- Nuveen, LLC Added+$44.9M
- JPMorgan Chase & Co Added+$41.7M
- Marshall Wace, LLP New+$41.6M
- Panagora Asset Management Inc New+$40.1M
- Pictet Asset Management Holding SA Added+$30.6M
Biggest sellers in Q2 2026
- Wellington Management Group LLP Trimmed-$205M
- Holocene Advisors, LP Sold out-$88.3M
- Citadel Advisors LLC Trimmed-$75.6M
- FMR LLC Trimmed-$70.7M
- Jennison Associates LLC Trimmed-$67.0M
- Commodore Capital LP Sold out-$48.0M
- Alyeska Investment Group, L.P. Trimmed-$36.3M
- MPM Bioimpact LLC Sold out-$34.2M
- Caligan Partners LP Trimmed-$30.4M
- Capital International Investors Trimmed-$18.9M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $965M and sold $914M; 125 added and 86 trimmed.
Schedule 13D and 13G filings on XENE
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-16Polar Capital Holdings Plc SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.Schedule 13G
- 2026-11-06T. Rowe Price Investment Management, Inc. SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.Schedule 13G
- 2026-02-10WELLINGTON MANAGEMENT GROUP LLP SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.Schedule 13G
- 2025-11-14JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.Schedule 13G
- 2025-07-17BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
Questions about XENE ownership
- Who owns XENE stock?
- 315 institutional investment managers reported XENE positions in their Form 13F filings for Q2 2026, holding 101,110,526 shares worth $6.1B in total. FMR LLC reported the largest position.
- Are funds buying or selling XENE?
- In Q2 2026, 46 managers opened new XENE positions, 125 added, 86 trimmed and 22 sold out. Managers that filed in both quarters added a net 733,459 shares.
- How current is this XENE institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to XENE by CUSIP. Options are left out. XENE news and filings · XENE insider trades · Top funds